AbSorber
Latest news
-
2013-02-01
The EUROSTAM consortium, with AbSorber AB as one of the collaborators, has been granted € 2.6M for developing a strategy to enhance the transplantation of highly sensitized patients -
2012-11-14
AbSorber announces that Abteilung Transplantationsimmunologie at Institut für Immunologie, Universität Heidelberg, Germany now operates as a reference laboratory for XM-ONE® testing in Germany and other European countries. -
2012-09-18
AbSorber announces they have entered into a study in collaboration with Rush University Medical Center, Chicago, IL, using the endothelial cell crossmatch XM-ONE®. -
2012-06-07
The transplantation unit at Jackson Memorial Hospital and the University of Miami, FL, USA has entered into a research project with AbSorber.
XM-ONE identifies patients at risk
XM-ONE, AbSorber's transplantation cross match, has been suggested to identify patients at risk of experiencing acute rejections after kidney transplantation. This was initially shown in 2009 when Breimer and co-workers published data from a multicenter study XM-ONE® (Breimer, M et al, Transplantation, Feb 2009). In a new publication from Johns Hopkins Medical School, Baltimore, MD (Jackson, AM et al, Transplantation, Apr 2011) these findings are confirmed.
AbSorber
AbSorber AB is a biotech company focused on developing products that increase the probability of transplantation success. XM-ONE®, the first AbSorber product on the market, is a CE-marked and FDA registered non-HLA transplantation crossmatch test kit. In contrast to current crossmatch testing, XM-ONE® rapidly detects antibodies specific for endothelial-specific antigens (AECA) as well as antibodies specific to major transplantation antigens. read more»
Highlighted Meeting
Olerup will be presenting the product line at EFI 2013.
Come and visit the booth to learn more about XM-ONE.
| Date: |
May 11-14, 2013 |
| Location: | Maastricht, The Netherlands |
Newsletter
Get information on XM-ONE® and stay tuned with AbSorber through our newsletter.